4.7 Review

Inherited platelet disorders: toward DNA-based diagnosis

Journal

BLOOD
Volume 127, Issue 23, Pages 2814-2823

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2016-03-378588

Keywords

-

Categories

Funding

  1. National Institute for Health Research (NIHR) BioResource-Rare Diseases
  2. NIHR
  3. Clinical Research Training Fellowship award from the MRC
  4. Imperial College London NIHR Biomedical Research Centre
  5. NIHR BioResource
  6. British Heart Foundation
  7. European Commission
  8. MRC
  9. NHS Blood and Transplant
  10. Wellcome Trust
  11. British Heart Foundation [RG/09/012/28096] Funding Source: researchfish
  12. Medical Research Council [MR/J011711/1] Funding Source: researchfish
  13. National Institute for Health Research [NF-SI-0513-10151, NF-SI-0510-10214, RP-PG-0310-1002] Funding Source: researchfish
  14. MRC [MR/J011711/1] Funding Source: UKRI

Ask authors/readers for more resources

Variations in platelet number, volume, and function are largely genetically controlled, and many loci associated with platelet traits have been identified by genomewide association studies (GWASs).(1) The genome also contains a large number of rare variants, of which a tiny fraction underlies the inherited diseases of humans. Research over the last 3 decades has led to the discovery of 51 genes harboring variants responsible for inherited platelet disorders (IPDs). However, the majority of patients with an IPD still do not receive a molecular diagnosis. Alongside the scientific interest, molecular or genetic diagnosis is important for patients. There is increasing recognition that a number of IPDs are associated with severe pathologies, including an increased risk of malignancy, and a definitive diagnosis can inform prognosis and care. In this review, we give an overview of these disorders grouped according to their effect on platelet biology and their clinical characteristics. We also discuss the challenge of identifying candidate genes and causal variants therein, how IPDs have been historically diagnosed, and how this is changing with the introduction of high-throughput sequencing. Finally, we describe how integration of large genomic, epigenomic, and phenotypic datasets, including whole genome sequencing data, GWASs, epigenomic profiling, protein-protein interaction networks, and standardized clinical phenotype coding, will drive the discovery of novel mechanisms of disease in the near future to improve patient diagnosis and management.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available